1. Home
  2. GSHR vs NMRA Comparison

GSHR vs NMRA Comparison

Compare GSHR & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GSHR
  • NMRA
  • Stock Information
  • Founded
  • GSHR 2024
  • NMRA 2019
  • Country
  • GSHR United States
  • NMRA United States
  • Employees
  • GSHR N/A
  • NMRA N/A
  • Industry
  • GSHR
  • NMRA
  • Sector
  • GSHR
  • NMRA
  • Exchange
  • GSHR NYSE
  • NMRA Nasdaq
  • Market Cap
  • GSHR 205.8M
  • NMRA 234.5M
  • IPO Year
  • GSHR 2025
  • NMRA 2023
  • Fundamental
  • Price
  • GSHR $10.15
  • NMRA $2.35
  • Analyst Decision
  • GSHR
  • NMRA Buy
  • Analyst Count
  • GSHR 0
  • NMRA 8
  • Target Price
  • GSHR N/A
  • NMRA $7.14
  • AVG Volume (30 Days)
  • GSHR 345.0
  • NMRA 2.6M
  • Earning Date
  • GSHR 01-01-0001
  • NMRA 08-06-2025
  • Dividend Yield
  • GSHR N/A
  • NMRA N/A
  • EPS Growth
  • GSHR N/A
  • NMRA N/A
  • EPS
  • GSHR N/A
  • NMRA N/A
  • Revenue
  • GSHR N/A
  • NMRA N/A
  • Revenue This Year
  • GSHR N/A
  • NMRA N/A
  • Revenue Next Year
  • GSHR N/A
  • NMRA N/A
  • P/E Ratio
  • GSHR N/A
  • NMRA N/A
  • Revenue Growth
  • GSHR N/A
  • NMRA N/A
  • 52 Week Low
  • GSHR $9.97
  • NMRA $0.61
  • 52 Week High
  • GSHR $10.50
  • NMRA $17.19
  • Technical
  • Relative Strength Index (RSI)
  • GSHR N/A
  • NMRA 85.38
  • Support Level
  • GSHR N/A
  • NMRA $1.70
  • Resistance Level
  • GSHR N/A
  • NMRA $2.17
  • Average True Range (ATR)
  • GSHR 0.00
  • NMRA 0.30
  • MACD
  • GSHR 0.00
  • NMRA 0.11
  • Stochastic Oscillator
  • GSHR 0.00
  • NMRA 74.95

About GSHR GESHER ACQUISITION CORPORATION II ORD USD0.0001 CL A

Gesher Acquisition Corp II is a blank check company.

About NMRA Neumora Therapeutics Inc.

Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.

Share on Social Networks: